RedHill Biopharma Files 6-K, Details Hyloris Deal & Warrants
Ticker: RDHL · Form: 6-K · Filed: Sep 5, 2025 · CIK: 1553846
| Field | Detail |
|---|---|
| Company | Redhill Biopharma Ltd. (RDHL) |
| Form Type | 6-K |
| Filed Date | Sep 5, 2025 |
| Risk Level | medium |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: licensing-agreement, financial-reporting, warrants
TL;DR
RedHill 6-K out: Hyloris deal details, warrant values updated for Q2 2025.
AI Summary
RedHill Biopharma Ltd. filed a 6-K report for the period ending June 30, 2025. The filing includes information related to their Movantik product and an exclusive license agreement with Hyloris Pharmaceuticals SA, announced on February 24, 2025. The report also details fair value measurements for warrants as of June 30, 2025.
Why It Matters
This filing provides an update on RedHill's business activities, including a key licensing agreement and financial instrument valuations, which are important for investors assessing the company's strategic direction and financial health.
Risk Assessment
Risk Level: medium — The filing contains financial details and business updates that could impact the company's stock price, but it does not announce major negative events.
Key Numbers
- Q2 2025 — Reporting Period (Financial and business updates are for this period.)
Key Players & Entities
- RedHill Biopharma Ltd. (company) — Filer of the report
- Hyloris Pharmaceuticals SA (company) — Partner in an exclusive license agreement
- 2025-06-30 (date) — Reporting period end date
- 2025-02-24 (date) — Date of exclusive license agreement announcement
FAQ
What is the nature of the exclusive license agreement with Hyloris Pharmaceuticals SA?
The filing references an 'ExclusiveLicenseAgreementWithHylorisPharmaceuticalsSaMember' announced on February 24, 2025, indicating a significant partnership.
What financial instruments are specifically valued in this report?
The report details 'FairValueOfWarrantsMember' as of June 30, 2025, including measurements based on historical volatility and interest rates.
What product is mentioned in relation to RedHill's business operations?
The product 'Movantik' is mentioned in the context of RedHill's operations for the period January 1, 2025, to June 30, 2025.
When was the reporting period for this 6-K filing?
The 'CONFORMED PERIOD OF REPORT' is listed as 20250630, indicating the period ending June 30, 2025.
What is RedHill Biopharma's primary industry classification?
RedHill Biopharma Ltd. is classified under 'PHARMACEUTICAL PREPARATIONS [2834]'.
Filing Stats: 353 words · 1 min read · ~1 pages · Grade level 8 · Accepted 2025-09-05 07:06:42
Filing Documents
- rdhl-20250630x6k.htm (6-K) — 62KB
- rdhl-20250630xex99d1.htm (EX-99.1) — 223KB
- rdhl-20250630xex99d2.htm (EX-99.2) — 429KB
- rdhl-20250630xex99d1001.jpg (GRAPHIC) — 7KB
- 0001558370-25-011883.txt ( ) — 2686KB
- rdhl-20250630.xsd (EX-101.SCH) — 35KB
- rdhl-20250630_cal.xml (EX-101.CAL) — 43KB
- rdhl-20250630_def.xml (EX-101.DEF) — 111KB
- rdhl-20250630_lab.xml (EX-101.LAB) — 233KB
- rdhl-20250630_pre.xml (EX-101.PRE) — 161KB
- rdhl-20250630x6k_htm.xml (XML) — 330KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. REDHILL BIOPHARMA LTD. (the "Registrant") Date: September 5, 2025 By: /s/ Dror Ben-Asher Name: Dror Ben-Asher Title: Chief Executive Officer 2